Technical Analysis for ARQL - ArQule, Inc.

Grade Last Price % Change Price Change
grade B 4.78 2.14% 0.10
ARQL closed up 2.14 percent on Monday, March 18, 2019, on 56 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical ARQL trend table...

Date Alert Name Type % Chg
Mar 18 Wide Bands Range Expansion 0.00%
Mar 15 1,2,3 Pullback Bullish Bullish Swing Setup 2.14%
Mar 15 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 2.14%
Mar 15 Volume Surge Other 2.14%
Mar 15 Calm After Storm Range Contraction 2.14%
Mar 15 NR7 Range Contraction 2.14%
Mar 15 Wide Bands Range Expansion 2.14%
Mar 14 Outside Day Range Expansion -1.65%
Mar 14 Wide Bands Range Expansion -1.65%
Mar 13 Calm After Storm Range Contraction -7.00%

Older signals for ARQL ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
ArQule, Inc., a clinical-stage biotechnology company, engages in the research and development of cancer therapeutics directed toward molecular targets and biological processes. Its lead product candidate tivantinib is an inhibitor of the c-Met receptor tyrosine kinase and its biological pathway, which is in Phase 3 clinical trial for the treatment of non-small cell lung and liver cancer; and Phase 2 clinical trial for the treatment of colorectal cancer. The company is also involved in the development of ARQ 087, an inhibitor of fibroblast growth factor receptor; ARQ 621, an inhibitor of the Eg5 kinesin motor protein; and ARQ 736, an inhibitor of the RAF kinases, which are in Phase 1 clinical development, as well as ARQ 761, an activator of the E2F-1 damage response/checkpoint pathway. It has partnership agreement with Daiichi Sankyo Co., Ltd. and Kyowa Hakko Kirin Co., Ltd. for implementing a clinical development program designed to realize the broad potential of tivantinib as a single agent; and in combination with other anti-cancer therapies in various disease indications. In addition, the company has research collaboration with Daiichi Sankyo Co., Ltd. to discover selective inhibitors of two kinases in the field of oncology based on its ArQule Kinase Inhibitor Platform (AKIP) technology. ArQule, Inc. was founded in 1993 and is headquartered in Woburn, Massachusetts.
Chemistry Biotechnology Cancer Disease Organic Chemistry Colorectal Cancer Cancer Therapeutics Cancer Therapies Ethers Tyrosine Kinase Inhibitors Tyrosine Kinase C Met Kinase Treatment Of Colorectal Cancer
Is ARQL a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 7.21
52 Week Low 2.23
Average Volume 1,330,336
200-Day Moving Average 4.5179
50-Day Moving Average 3.7154
20-Day Moving Average 4.042
10-Day Moving Average 4.694
Average True Range 0.4095
ADX 32.88
+DI 35.4094
-DI 13.2499
Chandelier Exit (Long, 3 ATRs ) 4.8815
Chandelier Exit (Short, 3 ATRs ) 4.3785
Upper Bollinger Band 5.6615
Lower Bollinger Band 2.4225
Percent B (%b) 0.73
BandWidth 80.133597
MACD Line 0.405
MACD Signal Line 0.3162
MACD Histogram 0.0888
Fundamentals Value
Market Cap 340.21 Million
Num Shares 71.2 Million
EPS -0.38
Price-to-Earnings (P/E) Ratio -12.58
Price-to-Sales 29.83
Price-to-Book 7.11
PEG Ratio -0.47
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.22
Resistance 3 (R3) 5.23 5.09 5.14
Resistance 2 (R2) 5.09 4.98 5.09 5.12
Resistance 1 (R1) 4.94 4.91 5.02 4.93 5.09
Pivot Point 4.80 4.80 4.84 4.80 4.80
Support 1 (S1) 4.65 4.69 4.73 4.64 4.47
Support 2 (S2) 4.51 4.62 4.51 4.44
Support 3 (S3) 4.36 4.51 4.42
Support 4 (S4) 4.35